Search our team at AdventHealth Research Institute
-
Efficacy of the AAP discharge recommendations to decrease emergency room visit within 14 days after discharge in well late preterm newborns
This study is currently enrolling.Associated Conditions: NeonatalResearch Area: Pediatrics ResearchResearch Location: Celebration, Florida -
NCT05858164
An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...
-
NCT06307795
A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in...
-
NCT05914116
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Celebration, FloridaThe main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
-
NCT03671889
Assessment of Safety and Efficacy of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients with Probable Alzheimer’s Disease
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Celebration, FloridaThe result of this study will help us determine whether blood-brain barrier disruption (BBBD) with Exablate is a safe procedure in the brains of patients with Alzheimer’s Disease. The purpose of this...
-
NCT05592626
CP-START-001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is
To test the safety of study drug STAR0602. To see how well different doses of the study drug STAR0602 are tolerated in different groups of patients. To understand... -
NCT06026410
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect... -
NCT05639751
PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information...
-
NCT04561362
BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Celebration, Florida -
NCT05614739
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaAN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
-
NCT05176483
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaYou are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...
-
NCT04140526
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC...